Metabolic / GLP-1
GOD of GODs Stack
The GOD Stack (Retatrutide + MOTS-c + Tesamorelin) combined with KLOW (BPC-157 + TB-500 + GHK-Cu + KPV) — a seven-peptide research blend covering metabolic, mitochondrial and healing axes simultaneously.
Quick facts
Molecular weight
4,731 Da
Half-life
144 h
Frequency
weekly
Admins / wk
1
Routes
SubQ
Typical dose
500 mcg–12.0 mg
Mechanism & positioning
The GOD Stack (Retatrutide + MOTS-c + Tesamorelin) combined with KLOW (BPC-157 + TB-500 + GHK-Cu + KPV) — a seven-peptide research blend covering metabolic, mitochondrial and healing axes simultaneously.
Researched for: metabolic recomposition, mitochondrial function, connective-tissue repair.
Blend composition
Reconstitution defaults
Default vial
140 mg
BAC water
4 mL
Concentration
35000 mcg/mL
Doses per vial
~280
Calculate with this peptide
Dosage Calculator
Pre-filled for 500 mcg from a 140 mg vial in 4 mL BAC water.
Reconstitution Calculator
Auto-fills 140 mg + 4 mL BAC water + 500 mcg target dose.
Half-Life Calculator
Simulates steady-state at 500 mcg weekly.
Titration Schedule Builder
Stepwise escalation from 500 mcg to 12.0 mg.
Stack Builder
Plots the per-component weekly schedule for the 7-peptide blend.
Related peptides in the Metabolic / GLP-1 class
Semaglutide
A long-acting GLP-1 receptor agonist researched for its role in glucose-dependent insulin secretion and reduced gastric emptying.
Tirzepatide
A dual GIP and GLP-1 receptor agonist investigated for superior weight and glycaemic outcomes versus selective GLP-1 agonists.
Retatrutide
A triple agonist of GIP, GLP-1, and glucagon receptors currently in late-phase research for obesity and metabolic indications.
AOD-9604
A fragment of the C-terminus of human GH researched for stimulating lipolysis without affecting blood glucose or IGF-1.
SLU-PP-332
A small-molecule pan-ERR agonist investigated in preclinical models for inducing exercise-mimetic mitochondrial gene expression in muscle and adipose tissue.
5-Amino-1MQ
A small-molecule selective NNMT inhibitor investigated in preclinical models for reducing methyl-group sequestration in adipose tissue and restoring NAD+/SAM balance.